Nanobiotix S.A.
ENXTPANANO arrives at its June 5 earnings event on a sharp divergence — up 18% over the past month, down 8% across the past week, and closing yesterday at €31.24 after a 3.7% single-day bounce. That tug-of-war between the recent run and the late pullback defines the setup. The lending market sends an unambiguous message: this is not a crowded short. Availability has climbed back…
NANO cost to borrow explodes to 65.77% as of June 1st, up 537% over one week from 11.31%.
Snapshot as of 5 Jul 2026
NANO arrives at its June 5 earnings event on a sharp divergence — up 18% over the past month, down 8% across the past week, and closing yesterday at €31.24 after a 3.7% single-day bounce. That tug-of-war between the…
Nanobiotix heads into its May 22 results carrying a sharp contradiction: clinical data strong enough to impress oncologists, yet a stock that just shed 10% in a single session. The immediate catalyst is a striking…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NANO — free to start on ORTEX.
Sign up for free →Open NANO on ORTEX